We are counting on public support to encourage early adoption of this important infection prevention technology in our healthcare facilities. Lives and better patient outcomes are at stake as so many of our current antibiotics have become less effective against a growing number of superbugs. Everyone now knows of someone who has died of an infection; this was not the case when I was growing up.
“In addition to decreasing surgical site infections, the project raised awareness of the importance of preventing infections, increased communication and teamwork at multiple levels and across numerous services and departments, and also promoted antimicrobial stewardship” ~BC Patient Safety & Quality Council
Wow, we couldn’t be more excited by this news!
Dr. Elizabeth Bryce and her team at Vancouver General Hospital (VGH) have been awarded the BC Quality Awards in the Getting Better category for their work implementing MRSAid Photodisinfection System and body wipes into their perioperative center.
This award is given to an initiative focused on improving care for acute illness or injury. Between June 2011 and May 2012, the team at VGH decolonized the noses of 5,300 patients using MRSAid. This procedure was done just prior to surgery, destroying any harmful bacteria that resides in the patient’s nose, and thus reducing their risk of developing an infection after surgery.
“It takes less than five minutes and it’s not painful,” said Dr. Wong, one of the dedicated team members at VGH. “Photodisinfection has several distinct advantages. It is not subject to any type of drug resistance and it doesn’t develop drug resistance.”
Left: Carolyn Cross, our CEO and Chairman. Right: Dr. Elizabeth Bryce, Champion For Change
Today is a proud moment for all of us. We’re here to honor a visionary doctor for championing an unheralded change in infection control – Dr. Elizabeth Bryce. Dr. Bryce is the recipient of the inaugural Champion For Change Award for her outstanding leadership in championing the VGH-MRSAid quality improvement project.
“Congratulations to Dr. Bryce on her well deserved recognition. To us, she most certainly is a champion of change and innovation. Her dedicated team at Vancouver General Hospital did a superb job integrating a new protocol into their surgical procedures, trailblazing the path for better patient outcomes.” Carolyn Cross, CEO & Chairman of Ondine Biomedical Inc.
The award, given to her by the Women Presidents’ Organization and GroYourBiz, recognizes global leaders who envision better ways of benefitting their community. “I’m honored to be recognized … I’m even more thrilled about the evidence-based results we are seeing from the use of MRSAid to save lives – and time – and money. Our team’s achievements are a world’s first, an enormous breakthrough for infection control and a huge coup for VGH.”
Watch the video below to see Dr. Bryce and her dedicated team at VGH discuss MRSAid.
Today is a very proud day for all of us. We can’t thank the amazing team at Vancouver General Hospital enough for their willingness to champion innovation and change. The results of this project mark a global first for photodisinfection as a non-antibiotic approach to reducing surgical site infections.
We have a very busy week ahead of us, so please stay tuned to this blog as we’ll be bringing you a lot more updates over the next few days.
Over the coming year, the world will learn more about our MRSAid™ photodisinfection technology and its ability to prevent surgical site infections. The last patients in the year long quality improvement program at Vancouver General Hospital (VGH) will be treated next month, giving us a chance to look retrospectively at how surgical site infections were affected at this major hospital. This program, involving over 5,000 patients at VGH, sought to reduce infections in all patients undergoing cardio, vascular, neurological, thoracic, breast, spinal and orthopaedic surgeries. Data from this analysis is expected in the late fall and results are expected to be announced at Infection Control Conferences in 2013.
People who carry MRSA or MSSA are at much greater risk of self infection when they are immunocompromised and weakened after surgery. Up to 30% of patients are simply unable to defend themselves from the tenacious bacteria called Staphylococcus aureus which lie dormant in the nose, waiting for opportunities to invade the body. Eliminating the bacteria carried in the nose prior to surgery has been proven to reduce the rate of surgical site infections. From a number of other studies (including Bode et al “Preventing SSIs In Nasal Carriers of Staph”), we have learned that eliminating both MRSA and MSSA from the nose prior to surgery reduces surgical site infections (SSIs) by up to 56% and total healthcare-associated infections (HAIs) by up to 79% in non-surgical admissions.
Our MRSAid™ Photodisinfection procedure has been well received at VGH and represents a promising approach to improve patient safety in other healthcare facility settings… Photodisinfection (is) ideal for hospital settings as it eliminates the need for patient compliance as it can be administered just prior to surgery- Carolyn Cross, Chairman and CEO of Ondine.
Less than a year ago, Vancouver General Hospital implemented the MRSAid™ Photodisinfection System as part of a year-long infection control Quality Improvement Project. Since then, we are very pleased to announce that we have treated over 2,500 patients, making this one of the largest PDT studies in the world. The project is being undertaken with the objective of reducing the incidence of surgical site infections in selected surgical populations.
Many people do not know that the nose is the primary site for bacteria colonization. The average person touches their nose more than 100 times a day, and if they touch their nose and then touch their surgical site, they are at risk of giving themselves an infection that was completely preventable. Many studies have demonstrated a significant reduction in surgical site infections after nasal decolonization of both Staph and MRSA. It is therefore critical to continue the development of non-antibiotic treatments that eliminate potentially deadly bacteria from the nose.
In today’s world, a higher degree of exchange is taking place between places through commerce and travel, and contact with new strains of bacteria is now becoming commonplace. Even more disconcerting is certain bacteria have begun to develop resistance to last line treatments such as Vancomycin.
Most people have never heard of Vancomycin and they are lucky. In a recent survey, three out of four doctors considered Vancomycin as the leading treatment for MRSA infections. Vancomycin doesn’t allow common types of bacteria to latch onto the cells in your body and because of this, many of the bacteria will die. The treatment for MRSA is one of six “indications” for which Vancomycin is restricted by the U.S. Centers for Disease Control and Prevention. This is because the more an antibiotic is used, the more resistant bacteria can develop. As a result, we should restrict usage to the most serious indications and limit antibiotic resistance. Read more »
MRSAidTM would like to congratulate Dr. Cale Street on being profiled on CEO Clips where he discusses the severity of Healthcare-Associated Infections (HAIs) and future plans for MRSAidTM. Dr. Street touches upon the seriousness of superbugs that are becoming resistant to antibiotics and subsequently resulting in difficult to treat HAIs.
MRSAidTM is currently being used at Vancouver General Hospital for patients undergoing select surgeries in order to reduce the risk of developing post-surgical site infections. Since MRSAidTMdoes not generate bacterial resistance, this is a milestone in the fight against HAIs and antibiotic resistant superbugs. Watch the video below:
Every year on April 7th, we celebrate World Health Day to mark the founding of the World Health Organization (WHO). Under this year’s theme of “Combating Drug Resistance,” the WHO is challenging healthcare professionals around the world to take action and implement change to address the growing problem of antibiotic resistance. Ondine is pleased to be able to respond to this challenge by entering into an innovative partnership with one of Canada’s largest hospital to introduce a novel non-antibiotic decolonization therapy aimed at reducing hospital-acquired infections (HAI’s).